AVI to Present at Paulson SmallCap Conference.Business Editors, Health/Medical Writers PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 6, 2002 AVI BioPharma, Inc. (Nasdaq:AVII)(Nasdaq:AVIIW)(Nasdaq:AVIIZ), today announced that it will present at the 25th annual SmallCap Conference on Thursday, Nov. 7, 2002. The conference, sponsored by the Paulson Investment Company, Inc., will be held at the Waldorf-Astoria in New York Nov. 6-7. CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Denis Denis, king of Portugal: see Diniz. R. Burger, Ph.D., and President and COO Alan P. Timmins will present an overview of AVI's technology platforms on Nov. 7 at 10:45 a.m., 11:15 a.m., 11:45 a.m., 3:30 p.m., 4 p.m. and 4:30 p.m. "We are pleased to have been selected as one of 20 emerging growth companies to present at this conference," said Dr. Burger. "The conference will provide AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples. with an opportunity to inform key investors about AVI's unique technology platform and latest activities." To attend the conference, those interested should contact Kellie Davis at 503/243-6027 or send e-mail to kmdavis@paulsoninvestment.com. Attendees may also preregister pre·reg·is·ter v. pre·reg·is·tered, pre·reg·is·ter·ing, pre·reg·is·ters v.intr. To take part in preregistration. v.tr. To enroll (a student) during a period of preregistration. for the event online at http://www.paulsoninvestment.com/conferences.htm. About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: NEUGENE(R) antisense drugs and cancer immunotherapy. Its lead cancer agent, AVICINE(R), a therapeutic cancer vaccine, has completed three Phase II trials in colorectal and pancreatic cancer and is initiating a Phase III pivotal trial in pancreatic cancer, with a supporting study in colorectal cancer. The first application of its NEUGENE compounds, Resten-NG(TM), is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders by inhibiting the production of a cellular transcription factor, the oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. c-myc. It is currently in Phase II trials for restenosis and in a Phase I/II trial for cancer. AVI has completed a Phase I NEUGENE antisense study that successfully down-regulated the liver enzyme cytochrome P450 and modified drug metabolism, and also recently completed a Phase I/II trial in polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. . More information about AVI is available on the Company's Web site at http://www.avibio.com/. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion